Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations

Journal of the American Society of Nephrology

Volumn 16, Issue 10, 2005, Pages 3027-3037

  Pohl, Marc A ^a   Blumenthal, Samuel ^b   Cordonnier, Daniel J ^c   De Alvaro, Fernando ^d   DeFerrari, Giacomo ^e   Eisner, Gilbert ^f   Esmatjes, Enric ^g   Gilbert, Richard E ^h   Hunsicker, Lawrence G ⁱ   Lopes De Faria, Jose B ^j   Mangili, Ruggero ^k   Moore, Jack ^f   Reisin, Efrain ^l   Ritz, Eberhard ^m   Schernthaner, Guntram ⁿ   Spitalewitz, Samuel ^o   Tindall, Hilary ^p   Rodby, Roger A ^q   Lewis, Edmund J ^q  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIV GRENOBLE ALPES   (France)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e UNIVERSITY OF GENOA   (Italy)

^f WASHINGTON HOSPITAL CENTER   (United States)

^g HOSPITAL CLÍNIC   (Spain)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ UNIVERSITY OF IOWA   (United States)

^j UNIVERSITY OF CAMPINAS   (Brazil)

^k BOLOGNINI HOSPITAL   (Italy)

^l LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^m UNIVERSITY OF HEIDELBERG   (Germany)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^p NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^q RUSH UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR; IRBESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; RANDOMIZED CONTROLLED TRIAL;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; TETRAZOLES;

EID: 33644912981     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004110919     Document Type: Article

References (36)

1. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 287: 2570-2581, 2002
2. Perneger TV, Brancati F, Whelton PK, Klag MJ: End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 121: 912-918, 1994
3. United States Renal Data System: USRDS 1999 Annual Data Report, National Institutes of Health; National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, 1999, pp 25-164
4. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde RD, Raz I; for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
5. Hunsicker LG, Atkins RC, Lewis JB, Braden G, de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ; for the Collaborative Study Group: Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int 66: S99-S101, 2004
6. Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Lewis EJ; for the Collaborative Study Group: The irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics. Nephrol Dial Transplant 15: 487-497, 2000
7. The Sixth Report of the Joint Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157: 2413-2446, 1997
8. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
9. Grambsch P, Therneau T: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526, 1994
10. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; for the Collaborative Study Group: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138: 542-549, 2003
11. Middleton JP, Lewis JB, for the Collaborative Study Group: Predictors of renal outcome in type 2 diabetic nephropathy [Abstract]. J Am Soc Nephrol 13: 249A, 2002
12. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ; on behalf of the Collaborative Study Group: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45: 281-287, 2005
13. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; for the AIPRD Study Group: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. Ann Intern Med 139: 244-253, 2003
14. Mogensen CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 36: 383-388, 1976
15. Parving HH, Rossing P, Hommel E, Smidt UM: Angiotensin-converting enzyme inhibition in diabetic nephropathy: Ten years' experience. Am J Kidney Dis 26: 99-107, 1995
16. Hostetter TH, Troy JC, Brenner BM: Glomerular haemodynamics in experimental diabetes mellitus. Kidney Int 19: 410-415, 1981
17. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986
18. Kimura K, Tojo A, Nanba S, Matsuoka H, Sugimoto T: Morphometric analysis of arteriolar diameters in experimental nephropathies: Application of microvascular casts. Virchows Arch A Pathol Anal Histopathol 417: 319-323, 1990
19. Hill GS, Hetides D, Bariéty J: Morphometric study of arterioles and glomeruli in the aging kidney suggests focal loss of autoregulation. Kidney Int 63: 1027-1036, 2003
20. Hayashi K, Epstein M, Loutzenhiser R, Forster H: Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: Role of eicosanoid derangements. J Am Soc Nephrol 2:1578-1586, 1992
21. Dillon JJ: The quantitative relationship between treated blood pressure and progression of diabetic renal disease. Am J Kidney Dis 22: 798-802, 1993
22. Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: Role of blood pressure. Kidney Int 35: 670-674, 1989
23. Toto R, Mitschell HC, Smith RD, Lee HC, McIntire D, Pettinger WA: Strict blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 48: 851-858, 1995
24. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; for the RENAAL Study Group: Effects of blood pressure level on progression of diabetic nephropathy. Arch Intern Med 163: 1555-1565, 2003
25. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; for the Collaborative Study Group: Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 16: 2170-2179, 2005
26. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP; for the INDIANA Project Steering Committee: J-shaped relationship between blood pressure and mortality in hypertensive patients: New insights from a meta-analysis of individual-patient data. Ann Intern Med 136:438-448, 2002
27. Hasebe N, Kido S, Ido A, Kenjiro K: Angiographical study in angina with hypertension induced insults (ASAHI) investigators. Reverse J-curve relation between diastolic blood pressure and severity of coronary artery lesion in hypertensive patients with angina pectoris. Hypertens Res Clin Exp 25: 381-387, 2002
28. Peterson JD, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker G, King AJ, Klahr S, Massry SG, Seifter JL; Modification of Diet in Renal Disease (MDRD) Study Group: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754-762, 1995
29. Sawicki PT, Muhlhauser I, Didjurgeit U, Baumgartner A, Bender R, Berger M: Intensified antihypertensive treatment is associated with improved survival in type I diabetic patients with nephropathy. J Hypertens 13: 933-938, 1995
30. Lewis JB, Hunsicker LG, Bain RP, Lewis EJ; for the Collaborative Study Group: Angiotensin converting enzyme inhibition in diabetic nephropathy. Kidney Int 45[Suppl 45]: S156-S160, 1994
31. The GISEN Group (Gruppo Italiano di Studi Epidemiolo- gici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
32. Maschio G, Alberti D, Janin G; the Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945, 1996
33. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ; for the Collaborative Study Group: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 34: 809-817, 1999
34. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 10: 1963-1974, 1995
35. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998
36. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252, 2003